Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| MACROGENICS INCMGNX · Entity 6104 | Senior VP, GC, and Secretary | August 19, 2026 | August 20, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
MACROGENICS INC
Report date August 19, 2026 · Filed August 20, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2026-08-19 transaction · row 1
1 source rowRow 1 · 2026-08-19 · Sale · Disposed 31,105 · Balance 0 F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 20, 2026. F2: This transaction was executed in multiple trades at prices ranging from $4.12 to $4.24. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 20, 2026.
F2: This transaction was executed in multiple trades at prices ranging from $4.12 to $4.24. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 22, 2023 Filed Feb 24, 2023 21:35 UTC | MACROGENICS INC MGNX · Entity 6104 | Tax withholdingCommon Stock | 3,378 | $6.55 | $22,125.90 |
DisclosureSEC source: 0001125345-23-000041 · wf-form4_167727448264875.xml · nonDerivative · entry 2 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,372 Read SEC document |
| February 22, 2023 Filed Feb 24, 2023 21:35 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 8,750 | $0.00 | $0.00 |
DisclosureSEC source: 0001125345-23-000041 · wf-form4_167727448264875.xml · nonDerivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: On February 22, 2022 the reporting person was granted 35,000 restricted stock units, 25% of which vested on February 22, 2023 and 75% of which will vest two years after the date of grant. Restricted stock units convert into the Company's stock on a one-for-one basis. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:29 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 40,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-23-000034 · wf-form4_167666936780166.xml · derivative · entry 2 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. F3 · derivative.expiration_date: The RSUs will vest as to 33% of the total shares one year after the date of grant and 33% each year thereafter. Read SEC document |
| February 15, 2023 Filed Feb 17, 2023 21:29 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee stock option (right to buy) · Derivative | 170,000 | $0.00 Strike: $4.82 | $0.00 |
DisclosureSEC source: 0001125345-23-000034 · wf-form4_167666936780166.xml · derivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,000 Underlying: Common Stock · 170,000 shares Expires 2033-02-15 F1 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 00:48 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantRestricted Stock Unit · Derivative | 35,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001125345-22-000030 · wf-form4_164575007381460.xml · derivative · entry 2 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,000 Underlying: Common Stock · 35,000 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit (RSU) represents a contingent right to receive one share of the Issuer's common stock. F3 · derivative.exercise_date: The RSUs will vest as to 25% of the total shares one year after the date of grant and 75% two years after the date of grant. F3 · derivative.expiration_date: The RSUs will vest as to 25% of the total shares one year after the date of grant and 75% two years after the date of grant. Read SEC document |
| February 22, 2022 Filed Feb 25, 2022 00:48 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee stock option (right to buy) · Derivative | 70,000 | $0.00 Strike: $10.15 | $0.00 |
DisclosureSEC source: 0001125345-22-000030 · wf-form4_164575007381460.xml · derivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · Senior VP and General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2032-02-22 F1 · derivative.exercise_date: 12.5% of the shares underlying the grant become exercisable 6 months after the date of grant and an additional 6.25% of the shares underlying the grant become exercisable on the first day of each three-month period thereafter. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 00:55 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionEmployee stock option (right to buy) · Derivative | 21,749 | $0.00 Strike: $11.50 | $0.00 |
DisclosureSEC source: 0001125345-21-000038 · wf-form4_161533774001831.xml · derivative · entry 3 Peters Jeffrey Stuart · CIK 0001706903 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,251 Underlying: Common Stock · 21,749 shares Expires 2030-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 00:55 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 21,749 | $26.50 | $576,348.50 |
DisclosureSEC source: 0001125345-21-000038 · wf-form4_161533774001831.xml · nonDerivative · entry 2 Peters Jeffrey Stuart · CIK 0001706903 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2019. F2 · price: This transaction was executed in multiple trades at prices ranging from $26.50 to $26.63. The reporting person undertakes to provide to MacroGenics, Inc., any security holder of MacroGenics, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 08, 2021 Filed Mar 10, 2021 00:55 UTC | MACROGENICS INC MGNX · Entity 6104 | Exercise / conversionCommon Stock | 21,749 | $11.50 | $250,113.50 |
DisclosureSEC source: 0001125345-21-000038 · wf-form4_161533774001831.xml · nonDerivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,749 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 22, 2021 Filed Feb 24, 2021 23:04 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee stock option (right to buy) · Derivative | 90,000 | $0.00 Strike: $19.18 | $0.00 |
DisclosureSEC source: 0001125345-21-000027 · wf-form4_161420782742024.xml · derivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2031-02-22 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| July 02, 2020 Filed Jul 6, 2020 20:25 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 202 | $30.00 | $6,060.00 |
DisclosureSEC source: 0001125345-20-000116 · wf-form4_159406714373071.xml · nonDerivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on August 20, 2019. Read SEC document |
| February 20, 2020 Filed Feb 24, 2020 21:45 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee stock option (right to buy) · Derivative | 87,000 | $11.50 Strike: $11.50 | $1,000,500.00 |
DisclosureSEC source: 0001125345-20-000021 · wf-form4_158258071062899.xml · derivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 87,000 Underlying: Common Stock · 87,000 shares Expires 2030-02-20 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| February 21, 2019 Filed Feb 25, 2019 21:01 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee stock option (right to buy) · Derivative | 70,000 | $0.00 Strike: $21.88 | $0.00 |
DisclosureSEC source: 0001125345-19-000028 · wf-form4_155112844594088.xml · derivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 70,000 Underlying: Common Stock · 70,000 shares Expires 2029-02-21 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| February 06, 2019 Filed Feb 8, 2019 22:40 UTC | MACROGENICS INC MGNX · Entity 6104 | SaleCommon Stock | 68 | $30.00 | $2,040.00 |
DisclosureSEC source: 0001125345-19-000017 · wf-form4_154966563401465.xml · nonDerivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 202 F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on September 13, 2018. Read SEC document |
| March 02, 2018 Filed Mar 6, 2018 22:24 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantEmployee stock option (right to buy) · Derivative | 50,000 | $0.00 Strike: $28.94 | $0.00 |
DisclosureSEC source: 0001125345-18-000046 · wf-form4_152037507437531.xml · derivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · Acting General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-03-02 F1 · derivative.exercise_date: 12.5% of the options become exercisable 6 months after the date of grant and the remaining 87.5% shall vest in 14 substantially equal quarterly installments thereafter. Read SEC document |
| May 31, 2017 Filed Feb 12, 2018 22:17 UTC | MACROGENICS INC MGNX · Entity 6104 | GrantCommon Stock | 270 | $15.05 | $4,063.50 |
DisclosureSEC source: 0001125345-18-000018 · wf-form5_151847380869920.xml · nonDerivative · entry 1 Peters Jeffrey Stuart · CIK 0001706903 · Acting General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 270 F1 · kind: The reporting person is voluntarily reporting the acquisition of the issuer's common stock pursuant to the MacroGenics, Inc. Employee Stock Purchase Plan. This acquisition was exempt under both Rule 16b-3(d) and Rule 16b-3(c). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.